Cabozantinib activates TFEB-mediated autophagy to exert anti-tumor effects in hepatocellular carcinoma
In Vitro Cellular & Developmental Biology - Animal · 2026-05 · 62 (5) · 661-672
DOI: 10.1007/s11626-026-01161-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vitro Cellular & Developmental Biology - Animal, online erschienen am 08.04.2026. Verfasst von Cheng Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Me…. Hauptthemen laut MEDLINE: Autophagy, Liver Neoplasms, Carcinoma, Hepatocellular, Anilides. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Autophagy signaling plays a crucial yet complex role in hepatocellular carcinoma (HCC), influencing tumor progression and treatment response. Cabozantinib is an orally administered multi-kinase inhibitor used in the treatment of various advanced cancers, including renal cell carcinoma and HCC. However, its precise mechanisms of action in HCC require further elucidation. Our study first revealed elevated levels of phosphorylated TFEB (p-TFEB, Ser142) in human HCC tissues and cell lines, indicating impaired TFEB-mediated autophagic flux in hepatocellular carcinoma. Treatment with Cabozantinib induced dose-dependent cytotoxicity, oxidative stress (increased ROS and decreased GSH), and mitochondrial dysfunction (reduced Complex IV activity and ATP production). Furthermore, Cabozantinib promoted autophagy activation, as evidenced by increased autophagosome formation, elevated LC3-II/I conversion and Beclin1 expression, and decreased p62 levels. Mechanistically, Cabozantinib inhibited TFEB phosphorylation at Ser142 and enhanced its nuclear translocation. Critically, TFEB knockdown abolished Cabozantinib-induced autophagy, confirming that the pro-autophagic effects are TFEB-dependent. These findings demonstrate that Cabozantinib exerts its anti-tumor activity in HCC through activating TFEB-mediated autophagy pathway by inducing oxidative stress and mitochondrial damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110, Ganhe Road, Hongkou District, Shanghai, 200080, China.
- Department of Medical Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110, Ganhe Road, Hongkou District, Shanghai, 200080, Chin…
Förderung
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Zitieren
APA
Chen, C., Hu, Y., Zhang, C., & Zhou, X. (2026). Cabozantinib activates TFEB-mediated autophagy to exert anti-tumor effects in hepatocellular carcinoma. In Vitro Cellular & Developmental Biology - Animal, 62(5), 661-672. https://doi.org/10.1007/s11626-026-01161-3
Vancouver
Chen C, Hu Y, Zhang C, Zhou X. Cabozantinib activates TFEB-mediated autophagy to exert anti-tumor effects in hepatocellular carcinoma. In Vitro Cellular & Developmental Biology - Animal. 2026;62(5):661-672. doi:10.1007/s11626-026-01161-3
BibTeX
@article{Chen2026,
author = {Chen, Cheng and Hu, Yongjie and Zhang, Chenggang and Zhou, Xiaocui},
title = {Cabozantinib activates TFEB-mediated autophagy to exert anti-tumor effects in hepatocellular carcinoma},
journal = {In Vitro Cellular & Developmental Biology - Animal},
year = {2026},
volume = {62},
number = {5},
pages = {661--672},
doi = {10.1007/s11626-026-01161-3}
}
EUVIMED